Search results for "tips"

showing 10 items of 280 documents

Morphine potentiates the impairing effects of neuroleptics on two-way active conditioned avoidance response in male mice

2004

The dopaminergic and opioid systems have effects on the conditioned avoidance response (CAR), although the possible interaction between these systems on this behaviour has not been studied. The effects of morphine (12.6 mg/kg), haloperidol (0.075 mg/kg), sulpiride (20 mg/kg) and risperidone (0.1 mg/kg) alone as well as morphine combined with these dopamine (DA) antagonists on the acquisition and performance of the CAR were explored in mice. Morphine increased avoidances but this seemed secondary to a rise in activity levels. All DA antagonists impaired CAR in the acquisition phase but only haloperidol disrupted performance. The combination of morphine plus neuroleptics impaired acquisition …

MaleNarcoticsConditioning ClassicalPharmacologyAvoidance responseMiceEscape ReactionDopamineAvoidance LearningmedicineHaloperidolAnimalsBiological PsychiatryPharmacologyAnalysis of VarianceMice Inbred BALB CRisperidoneBehavior AnimalMorphinebusiness.industryDopaminergicDrug SynergismOpioidMorphineDopamine AntagonistsSulpiridebusinesshuman activitiesAntipsychotic Agentsmedicine.drugProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct

Effects of SCH 23390, Raclopride, and Haloperidol on Morphine Withdrawal-Induced Aggression in Male Mice

1999

Abstract RODRIGUEZ-ARIAS, M., J. PINAZO, J. MINARRO AND L. STINUS. Effects of SCH 23390, raclopride, and haloperidol on morphine withdrawal-induced aggression in male mice. PHARMACOL BIOCHEM BEHAV 64(1) 123–130, 1999.—Dopamine seems to play a very important role in aggressive behavior observed in morphine withdrawal. The effect of SCH 23390 (0.5 mg/kg), raclopride (0.3 mg/kg), and haloperidol (0.1 mg/kg) on morphine withdrawal-induced aggression has been studied in this work. Mice were rendered dependent by a daily injection of morphine (2.5 mg/kg) for 14 days. Three different experiments were carried out with the objective to evaluate the antiaggressive effect of the dopamine antagonists o…

MaleNarcoticsmedicine.medical_specialtyNarcotic AntagonistsClinical BiochemistryPharmacologyToxicologyBiochemistryMiceBehavioral Neurosciencechemistry.chemical_compoundDopamineInternal medicineSalicylamidesmedicineHaloperidolAnimalsSocial BehaviorBiological PsychiatryPharmacologyRacloprideSCH-23390MorphineNaloxonebusiness.industryDopaminergicAntagonistDopamine antagonistBenzazepinesSubstance Withdrawal SyndromeAggressionEndocrinologychemistryRacloprideMorphineDopamine AntagonistsHaloperidolbusinessAntipsychotic Agentsmedicine.drugPharmacology Biochemistry and Behavior
researchProduct

Treatments used for obsessive-compulsive disorder-An international perspective.

2018

Objective The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive–compulsive disorder (OCD). Methods Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated. Results The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants. Fluoxetine (n = 972; 13…

MaleObsessive-Compulsive DisorderInternationalitymedicine.medical_treatmentDeep Brain StimulationSocial SciencesFluvoxamineBENZODIAZEPINASpharmacotherapyBenzodiazepines0302 clinical medicinePharmacology (medical)TERAPIA PSICOANALITICAPSICOFARMACOLOGIAantipsychotics; benzodiazepines; cross-cultural study; obsessive-compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitorsMiddle Aged3. Good healthExposure and response preventionantipsychotics; benzodiazepines; cross-cultural study; obsessive–compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitorsNeurologyPsychiatry and Mental HealthSerotonin Uptake Inhibitorscross-cultural studyAripiprazoleFemalebenzodiazepineSelective Serotonin Reuptake Inhibitorsmedicine.drugPsychosurgeryAntipsychotic AgentsAdultmedicine.medical_specialty:Ciências da Saúde [Ciências Médicas]Ciências Médicas::Ciências da SaúdeSerotonin reuptake inhibitor03 medical and health sciencesANTIPSICOTICOSobsessive–compulsive disorderselective serotonin reuptake inhibitorsmedicinePSICOTROPICOSHumansAntipsychoticPsychiatryFARMACOTERAPIAFluoxetineRisperidoneantipsychotics; benzodiazepines; cross-cultural study; obsessive–compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitors; Neurology; Neurology (clinical); Psychiatry and Mental Health; Pharmacology (medical)Science & Technologyselective serotonin reuptake inhibitorbusiness.industryTRASTORNO OBSESIVO COMPULSIVO030227 psychiatryantipsychoticPsychosurgeryantipsychoticsNeurology (clinical)business030217 neurology & neurosurgerySEROTONINAHuman psychopharmacology
researchProduct

Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic…

2021

Background Recent guidelines suggested a wider use of long-acting injectable antipsychotics (LAI) than previously, but naturalistic data on the consequences of LAI use in terms of discontinuation rates and associated factors are still sparse, making it hard for clinicians to be informed on plausible treatment courses. Objective Our objective was to assess, under real-world clinical circumstances, LAI discontinuation rates over a period of 12 months after a first prescription, reasons for discontinuation, and associated factors. Methods The STAR Network ‘Depot Study’ was a naturalistic, multicentre, observational prospective study that enrolled subjects initiating a LAI without restrictions …

MalePediatricsrespectively)0302 clinical medicineDelayed-Action PreparationBrief Psychiatric Rating ScalePharmacology (medical)he STAR Network ‘Depot Study’ prospectively followed 394 subjects initiating treatment with long-acting injections (LAIs) of antipsychotics under naturalistic conditions for 12 months. LAI discontinuation was frequent in everyday clinical practice in ItalyOriginal Research ArticleProspective StudiesProspective cohort studytreatmentMental DisordersHazard ratiowhereas more than half of participants initiating risperidone LAI and olanzapine LAI discontinued during the 12 months of follow-up (51.4 and 62.5%Psychiatric Status Rating ScaleMiddle Agedside efectsPsychiatry and Mental healthItalyMental DisorderFemalehe STAR Network ‘Depot Study’ prospectively followed 394 subjects initiating treatment with long-acting injections (LAIs) of antipsychotics under naturalistic conditions for 12 months. LAI discontinuation was frequent in everyday clinical practice in Italy occurring in almost 40% of the entire sample; side efects participant refusal to continue LAIs and LAIs no longer being required were the most frequently reported reasons for discontinuation. Paliperidone LAI and aripiprazole LAI were the least discontinued medications (33.9 and 35.4% respectively) whereas more than half of participants initiating risperidone LAI and olanzapine LAI discontinued during the 12 months of follow-up (51.4 and 62.5% respectively). In multivariate analysis being prescribed olanzapine LAI and poor medication adherence at baseline were signifcantly associated with higher discontinuation risk.HumanAntipsychotic Agentsmedicine.drugPsychopathologyAdultmedicine.medical_specialtyDiscontinuationFollow-Up StudieMedication Adherence03 medical and health sciencesmedicineHumansPaliperidoneAdverse effectSettore MED/25 - Psichiatriadiscontinuation ratesPsychiatric Status Rating Scalesrespectively). In multivariate analysisbusiness.industryLong-Acting Antipsychoticlong-acting injectable antipsychoticsSurvival AnalysisConfidence intervalparticipant refusal to continue LAIs and LAIs no longer being required were the most frequently reported reasons for discontinuation. Paliperidone LAI and aripiprazole LAI were the least discontinued medications (33.9 and 35.4%030227 psychiatryDiscontinuationProspective StudieAntipsychotic Agentoccurring in almost 40% of the entire sampleDelayed-Action PreparationsNeurology (clinical)business030217 neurology & neurosurgerybeing prescribed olanzapine LAI and poor medication adherence at baseline were signifcantly associated with higher discontinuation riskFollow-Up Studies
researchProduct

Effects of risperidone on conditioned avoidance responding in male mice

1998

The effects of risperidone (0.1, 0.5 and 1 mg/kg) on active avoidance behaviour of BALB/C mice were explored in three acquisition sessions and in one subsequent performance session. In the acquisition phase, risperidone-treated animals showed a decrease in avoidances and in crossings in the adaptation period and in the intertrial intervals (ITIs), and an increase in non-responses; intermediate and high doses also decreased defecation. In the performance phase, 0.5 and 1 mg/kg risperidone decreased avoidance responses, crossings in the adaptation period and ITI crossing, which also decreased with 0.1 mg/kg. Moreover, 0.5 mg/kg of risperidone increased escape responses and 1 mg/kg increased n…

MalePharmacologyMice Inbred BALB Cmedicine.medical_specialtyRisperidonebusiness.industryMale miceRisperidoneMicePsychiatry and Mental healthEndocrinologyAvoidance behaviourInternal medicineAvoidance LearningmedicineHigh dosesDecreased defecationAnimalsDefecationbusinessPsychomotor PerformanceAntipsychotic Agentsmedicine.drugBehavioural Pharmacology
researchProduct

Haloperidol does not antagonize the effects of stress on aggressive behaviour in mice.

1990

The possibility that antipsychotic drugs antagonize the behavioural effects of stress on agonistic behaviour has been explored. Male mice of the OF.1 strain were subjected to the following treatments: 1) Immobilization stress (ten or twenty minutes in duration), 2) haloperidol (three doses) and 3) immobilization stress (ten minutes) plus haloperidol. Individually housed experimental animals confronted standard opponents (anosmic animals) in ten-minute encounters in a neutral cage. Encounters were videotaped and behaviour evaluated, assigning times allocated by subjects to eleven broad behavioural categories. The data show that stress markedly decreases attack behaviour, but haloperidol does…

MaleRestraint Physicalmedicine.medical_specialtyDose-Response Relationship Drugmedicine.medical_treatmentMale miceExperimental and Cognitive PsychologyMice Inbred StrainsDevelopmental psychologyAggressionBehavioral NeuroscienceMiceEndocrinologyInternal medicinemedicineHaloperidolAgonistic behaviourAnimalsHaloperidolRestraint stressAntipsychoticPsychologyArousalAgonistic Behaviormedicine.drugPhysiologybehavior
researchProduct

Hippocampal oscillatory dynamics and sleep atonia are altered in an animal model of fibromyalgia: Implications in the search for biomarkers

2019

The pathogenesis of fibromyalgia is still unknown. Core symptoms include pain, depression, and sleep disturbances with high comorbidity, suggesting alterations in the monoaminergic system as a common origin of this disease. The reserpine-induced myalgia (RIM) model lowers pain thresholds and produces depressive-like symptoms. The present work aims to evaluate temporal dynamics in the oscillatory profiles and motor activity during sleep in this model and to evaluate if the model mimics the sleep disorders that occur in fibromyalgia patients. Hippocampal and electromyogram activity were recorded in chronically implanted rats. Following 3 days of basal recordings, reserpine was administered on…

MaleSleep Wake Disorders0301 basic medicinemyalgiaFibromyalgiaReserpineHippocampusElectromyographyHippocampal formationBiologyHippocampusRats Sprague-Dawley03 medical and health sciences0302 clinical medicineFibromyalgiaMonoaminergicmedicineAnimalsmedicine.diagnostic_testGeneral NeuroscienceChronic painElectroencephalographymedicine.diseaseBrain WavesSleep in non-human animalsRats030104 developmental biologymedicine.symptomSleepNeuroscience030217 neurology & neurosurgeryAntipsychotic AgentsJournal of Comparative Neurology
researchProduct

Antipsychotic prescription and mortality in hospitalized older persons

2016

Background: Recent scientific reports have shown that older persons treated with antipsychotics for dementia-related behavioural symptoms have increased mortality. However, the impact of these drugs prescribed during hospitalization has rarely been assessed. We aimed to investigate whether antipsychotics are associated with an increased risk of mortality during hospitalization and at 3-month follow-up in elderly inpatients. Methods: We analyzed data gathered during two waves (2010 and 2012) by the REPOSI (Registro Politerapie Società Italiana Medicina Interna). All new prescriptions of antipsychotic drugs during hospitalization, whether maintained or discontinued at discharge, were collect…

MaleSocio-culturaleOlder personAntipsychoticCognitionEconomicaAntipsychotics; Hospitalization; Mortality; Older persons; Gerontology; Geriatrics and Gerontology; Psychiatry and Mental HealthHumansMortalityPsychomotor AgitationAgedantipsychotics hospitalization mortality older personsAged 80 and overMental DisordersPatient DischargeHospitalizationantipsychoticsItalyantipsychotics; hospitalization; mortality; older personsPsychiatry and Mental Healtholder personsDementiaFemaleGeriatrics and GerontologyGerontologyAntipsychotic Agents
researchProduct

Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice

2008

Efflux transporters, like P-glycoprotein (P-gp), may limit the access of drugs to the brain via the blood-brain barrier. The antipsychotic drug risperidone and its active metabolite 9-hydroxyrisperidone (paliperidone) are substrates of P-gp. Motor behavior of P-gp deficient mice (mdr1a/1b (-/-, -/-)) and wild type animals on a rotarod after acute doses of risperidone or haloperidol, a nonsubstrate of P-gp, were analysed aiming to show that P-gp substrate properties of an antipsychotic drug have functional consequences. Behavioral tests revealed dose-dependent effects of 0.3-3 mg/kg risperidone in wild type animals 0.5-12 h after i.p. injection of the drug. In knockout mice the 0.3 mg/kg dos…

Malemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BTime Factorsmedicine.drug_classAtypical antipsychoticMotor ActivityPharmacologyMiceBehavioral NeurosciencePharmacokineticsInternal medicinePaliperidone PalmitatemedicineHaloperidolAnimalsPaliperidoneATP Binding Cassette Transporter Subfamily B Member 1Chromatography High Pressure LiquidMice KnockoutPaliperidone PalmitateRisperidoneBehavior AnimalDose-Response Relationship DrugChemistryDopamine antagonistBrainIsoxazolesRisperidonePyrimidinesEndocrinologyPsychotropic drugArea Under CurveHaloperidolATP-Binding Cassette TransportersAntipsychotic Agentsmedicine.drugBehavioural Brain Research
researchProduct

Resolution of enuresis with aripiprazole in children with psychiatric disorders: two case reports

2021

Abstract Background Aripiprazole is a third-generation atypical antipsychotic drug that acts as a stabilizer of the dopaminergic and serotonergic system. As partial agonist of the dopamine (D2) and serotonin (5-HT1A) receptors, it appears to be effective in reducing mania in patients with bipolar disorder, tics in Tourette Syndrome, aggression in schizophrenia and autism spectrum disorder. Enuresis has been reported among its side effects. Only a few studies, with conflicting results, have investigated the relationship between aripiprazole and enuresis. Case presentation We report the disappearance of enuresis in a Caucasian girl with intellectual disability and oppositional defiant disorde…

Malemedicine.medical_specialtyAutism Spectrum Disordermedicine.drug_classmedicine.medical_treatmentAripiprazoleAtypical antipsychoticCase ReportAtypical antipsychoticTourette syndrome03 medical and health sciences0302 clinical medicineEnuresismental disordersmedicineHumansBipolar disorderChildPsychiatryAntipsychoticbusiness.industryRGeneral MedicineEnuresismedicine.disease030227 psychiatrySchizophreniaSchizophreniaMedicineFemaleAripiprazolemedicine.symptombusinessMania030217 neurology & neurosurgeryAntipsychotic AgentsNocturnal Enuresismedicine.drugJournal of Medical Case Reports
researchProduct